Last reviewed · How we verify
MYL-1601D Product
MYL-1601D Product is a generic version of a medication that helps to lower blood sugar levels in people with type 2 diabetes.
MYL-1601D Product is a generic version of a medication that helps to lower blood sugar levels in people with type 2 diabetes. Used for Type 2 diabetes.
At a glance
| Generic name | MYL-1601D Product |
|---|---|
| Sponsor | Mylan Inc. |
| Drug class | SGLT2 inhibitor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
It works by stimulating the release of insulin from the pancreas and/or decreasing the amount of glucose produced by the liver. This helps to lower blood sugar levels and improve glycemic control.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
- Increased risk of urinary tract infections
- Dehydration
Key clinical trials
- Mylan Insulin Aspart Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MYL-1601D Product CI brief — competitive landscape report
- MYL-1601D Product updates RSS · CI watch RSS
- Mylan Inc. portfolio CI